About Enhancer

Enhancer ID: E_01_0395
Species: human
Position : chr2:15937740-15939740
Biosample name:
Experiment class : High+Lowthroughput
Enhancer type: Enhancer
Disease: Mammary cancer
Pubmed ID:  29928447
Enhancer experiment: Immunofluorescent staining,Whole genome amplification,CCP,
Enhancer experiment description: The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.

About Target gene

Target gene : --
Strong evidence: qRT-PCR,qPCR,ChIP,3C
Less strong evidence: RNA-Seq
Target gene experiment description: The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.;The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.

About TF

TF name : MYCN(MODED,N-myc,NMYC,ODED,bHLHe37)APC
TF experiment: Immunofluorescent staining,Whole genome amplification,CCP,
TF experiment description: The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.;The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.

About Function

Enhancer function : The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.
Enhancer function experiment: Immunohistochemical staining
Enhancer function
experiment description:		 The CTC-specific mutations were enhancer of zeste polycomb repressive complex 2 subunit, notch 1, AT-rich interaction domain 1A, serine/threonine kinase 11, fms related tyrosine kinase 3, MYCN proto-oncogene, bHLH transcription factor, APC, WNT signaling pathway regulator, and phosphatase and tensin homolog. The technique used by the present study was demonstrated to be effective at isolating CTCs at a sufficiently high purity for genomic analysis, and supported the use of comprehensive cancer panel analysis as a potential application for precision medicine.

About SNP

SNP ID: --

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
MYCN Hs_Pathways_Affected_in_Adenoid_Cystic_Carcinoma_WP3651_89271 wikipathways 27
APC Angiogenesis panther 141
APC APC truncation mutants have impaired AXIN binding reactome 14
APC Apoptotic cleavage of cellular proteins reactome 18
APC AXIN missense mutants destabilize the destruction complex reactome 14
APC Beta-catenin phosphorylation cascade reactome 17
APC Beta catenin degradation signaling (Canonical) ( C. elegans endoderm induction Wnt signaling pathway Diagram ) inoh 8
APC Beta catenin degradation signaling (Canonical) ( Canonical Wnt signaling pathway Diagram ) inoh 8
APC Beta catenin degradation signaling (Canonical) ( Drosophila Wingless/Wnt signaling pathway Diagram ) inoh 8
APC Beta catenin degradation signaling (Canonical) ( Mammalian Wnt signaling pathway Diagram ) inoh 8
APC Beta catenin degradation signaling (Canonical) ( Xenopus axis formation Wnt signaling pathway Diagram ) inoh 8
APC Beta catenin degradation signaling (Mammal) ( Mammalian Wnt signaling pathway Diagram ) inoh 8
APC Canonical Wnt signaling pathway pid 21
APC CDC42 signaling events pid 71
APC Deactivation of the beta-catenin transactivating complex reactome 42
APC Degradation of beta-catenin by the destruction complex reactome 67
APC Degradation of beta catenin pid 18
APC Direct p53 effectors pid 141
APC Disassembly of the destruction complex and recruitment of AXIN to the membrane reactome 31
APC Misspliced GSK3beta mutants stabilize beta-catenin reactome 15
APC Presenilin action in Notch and Wnt signaling pid 46
APC Regulation of CDC42 activity pid 31
APC Regulation of nuclear beta catenin signaling and target gene transcription pid 80
APC S33 mutants of beta-catenin aren't phosphorylated reactome 15
APC S37 mutants of beta-catenin aren't phosphorylated reactome 15
APC S45 mutants of beta-catenin aren't phosphorylated reactome 15
APC Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) pid 80
APC Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) ( C. elegans endoderm induction Wnt signaling pathway Diagram ) inoh 24
APC Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) ( Canonical Wnt signaling pathway Diagram ) inoh 24
APC Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) ( Drosophila Wingless/Wnt signaling pathway Diagram ) inoh 24
APC Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) ( Mammalian Wnt signaling pathway Diagram ) inoh 24
APC Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) ( Xenopus axis formation Wnt signaling pathway Diagram ) inoh 24
APC Stabilization and accumulation of cytoplasmic beta-catenin (Mammal) ( Mammalian Wnt signaling pathway Diagram ) inoh 24
APC T41 mutants of beta-catenin aren't phosphorylated reactome 15
APC Truncations of AMER1 destabilize the destruction complex reactome 14
APC Wnt netpath 118
APC Wnt signaling pathway kegg 135
APC Regulation of actin cytoskeleton kegg 210
APC Pathways in cancer kegg 321
APC Colorectal cancer kegg 63
APC Endometrial cancer kegg 52
APC Basal cell carcinoma kegg 51
APC Hs_DNA_Damage_Response_(only_ATM_dependent)_WP710_79974 wikipathways 36
APC Hs_Gastric_Cancer_Network_1_WP2361_86831 wikipathways 26
APC Hs_Copper_homeostasis_WP3286_89205 wikipathways 15
APC Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
APC Hs_White_fat_cell_differentiation_WP3946_90940 wikipathways 30
APC Hs_Brain-Derived_Neurotrophic_Factor_(BDNF)_signaling_pathway_WP2380_89803 wikipathways 80

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer

Enhancer associated SNPs